Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-03-20
2010-11-16
Saunders, David A (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07833724
ABSTRACT:
The present invention relates to methods of determining the immunogenic potential of a test product by comparing the immunogenic profile or fingerprint of the test product to the immunogenic profile or fingerprint of a reference product.
REFERENCES:
patent: 5135874 (1992-08-01), Esmon et al.
patent: 5147779 (1992-09-01), Esmon et al.
patent: 5470560 (1995-11-01), Martin, Jr.
patent: 5639440 (1997-06-01), Martin, Jr.
patent: 5667988 (1997-09-01), Barbas et al.
patent: 5766898 (1998-06-01), Loevborg
patent: 6045501 (2000-04-01), Elsayed et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6315720 (2001-11-01), Williams et al.
patent: 6420113 (2002-07-01), Buechler et al.
patent: 6555310 (2003-04-01), Gray et al.
patent: 6561976 (2003-05-01), Elsayed et al.
patent: 6561977 (2003-05-01), Williams et al.
patent: 6673580 (2004-01-01), Koren et al.
patent: 6686164 (2004-02-01), Olsen et al.
patent: 6755784 (2004-06-01), Williams et al.
patent: 2002/0160358 (2002-10-01), Schenerman et al.
patent: 2003/0054424 (2003-03-01), Allen et al.
patent: 2004/0175757 (2004-09-01), Olsen et al.
patent: 2004/0212508 (2004-10-01), Zweig
patent: 2005/0191692 (2005-09-01), Thompson et al.
Chamberlain, P., “Immunogenicity of therapeutic proteins: Part 1: Causes and clinical manifestations of immunogenicity,”The Regulatory Review 5:4-9, Ministry of Economic Development's Effective Markets Branch (2002).
Coan, T.D. and Ellis, R., “Generic Biologics: The Next Frontier,” inABN-AMRO, Coan, T.D. and Ellis, R., eds., The Netherlands (2001).
Dempster, A.M., “Nonclinical safety evaluation of biotechnologically derived pharmaceuticals,”Biotechnol Annu Rev 5:221-258, Elsevier Science B.V. (2000).
Esmon, P.C., et al., “Characterization of Recombinant Factor VIII and a Recombinant Factor VIII Deletion Mutant Using a Rabbit Immunogenicity Model System,”Blood 76:1593-1600, American Society of Hematology (1990).
“Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs,” U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 35 pages (2002).
Halder, M., “Three Rs Potential in the Development and Quality Control of Immunobiologicals,”Altex 18:13-47, Spektrum Akademischer Verlag (2001).
Hellendoorn, K., et al., “Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (Delmmunisation™)”Cancer Cell International 4:S20, BioMed Central Ltd (2004).
Ji, Q.C., et al., “Investigation of the Immunogenicity of a Protein Drug Using Equilibrium Dialysis and Liquid Chromatography Tandem Mass Spectrometry Detection,”Anal. Chem. 77:5529-5533, American Chemical Society (Sep. 2005).
Mintz, P.J., et al., “Fingerprinting the circulating repertoire of antibodies from cancer patients,”Nature Biotechnology 21:57-63, Nature Publishing Group (2002).
Mire-Sluis, A.R., et al., “Standardization: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products,”Journal of Immunological Methods 289:1-16, Elsevier B.V. (2004).
Moxness, M., et al., “Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal Antibodies,”Clinical Chemistry 51:1983-1985, American Association for Clinical Chemistry (Oct. 2005).
Schellekens, H., “Bioequivalence and the Immunogenicity of Biopharmaceuticals,”Nat Rev Drug Discov 1:457-462, Nature Publishing Group (2002).
Schellekens, H. and Ryff, J.-C., “‘Biogenerics’: the off-patent biotech products,”Trends in Pharmacological Sciences 23:119-121, Elsevier Science Ltd. (2002).
(Transcripts) “Drug Information Association, FDA/DIA Scientific Workshop on Follow-on Protein Pharmaceuticals, Breakout Session E: Immunogenicity Studies,” Marriott Crystal Gateway, Arlington, VA, 83 pages (Feb. 15, 2005).
Wadhwa, M., et al., “Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals,”Journal of Immunological Methods 278:1-17, Elsevier B.V. (2003).
International Search Report and Written Opinion for International Application No. PCT/US2007/006843, mailed on Nov. 27, 2007, United States Patent and Trademark Office, Alexandria, VA.
DiLiberti Charles E.
Liss Alan
Saunders David A
Sterne Kessler Goldstein & Fox P.L.L.C.
Teva Women's Health, Inc.
LandOfFree
Methods for comparing the immunogenicity of products and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for comparing the immunogenicity of products and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for comparing the immunogenicity of products and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197182